Live Analyst Rating Changes 3271 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Leland Gershell
OPCO
Leland Gershell
Wall Street Analyst
★★☆☆☆
#2289
on 13Foresight · ranked by our own returns
44%
Success Rate
-9.0%
Average Return
21 of 48 calls profitable · -10.5% vs benchmark
📈 Across the calls we could measure, roughly 44% of Leland Gershell's ratings turned a profit when each position was held for 1 year — averaging -9.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

99 Buy 9 Hold 0 Sell
Leland's Stock Coverage 55 ratings · 2026-06-27
Company Date Position Consensus Price Target 1-Yr Return
OKUR
OnKure Therapeutics
Jun 24, 2026 BUY Buy
+442.7% avg upside
13 analysts
$30.00
566.59% Upside
·
ARGX
Argenx Se
Jun 24, 2026 BUY Strong Buy
-15.8% avg upside
46 analysts
$1014.00
14.31% Upside
+4.2%
ENGN
enGene Holdings
Jun 22, 2026 HOLD Buy
+471.5% avg upside
13 analysts
·
FULC
Fulcrum Therapeutics
Jun 22, 2026 HOLD Hold
+132.0% avg upside
14 analysts
·
CAPR
Capricor Therapeutics
Jun 18, 2026 BUY Strong Buy
+88.0% avg upside
12 analysts
$54.00
104.14% Upside
+7.1%
ASND
Ascendis Pharma
Jun 15, 2026 BUY Strong Buy
+3.6% avg upside
24 analysts
$262.00
0.42% Upside
+3.5%
SABS
SAB Biotherapeutics
Jun 15, 2026 BUY Strong Buy
+178.5% avg upside
14 analysts
$14.00
268.46% Upside
·
SPRB
Spruce Biosciences
May 27, 2026 BUY Strong Buy
+82.6% avg upside
14 analysts
$230.00
317.29% Upside
-0.4%
TARA
Protara Therapeutics
May 20, 2026 BUY Strong Buy
+1115.6% avg upside
21 analysts
$28.00
579.66% Upside
-18.1%
URGN
Urogen Pharma
May 19, 2026 BUY Strong Buy
+9.9% avg upside
16 analysts
$40.00
15.88% Upside
+16.1%
CALC
CalciMedica
May 15, 2026 BUY Buy
+3403.1% avg upside
9 analysts
$10.00
1125.68% Upside
+30.3%
CLYM
Climb Bio
May 15, 2026 BUY Strong Buy
+40.4% avg upside
18 analysts
$18.00
37.53% Upside
+0.0%
EQ
Equillium
May 15, 2026 BUY Strong Buy
+185.9% avg upside
14 analysts
$7.00
129.44% Upside
+27.1%
CRNX
Crinetics Pharmaceuticals
May 11, 2026 BUY Strong Buy
+116.4% avg upside
20 analysts
$84.00
128.84% Upside
-8.9%
TRVI
Trevi Therapeutics
May 08, 2026 BUY Strong Buy
+11.5% avg upside
16 analysts
$24.00
32.19% Upside
-2.1%
CPRX
Catalyst Pharma
May 07, 2026 HOLD Strong Buy
-17.3% avg upside
15 analysts
+0.7%
OCGN
Ocugen
May 06, 2026 BUY Strong Buy
+519.8% avg upside
17 analysts
$10.00
566.64% Upside
-10.7%
VRDN
Viridian Therapeutics
Apr 13, 2026 HOLD Strong Buy
+90.3% avg upside
32 analysts
+8.8%
LXEO
Lexeo Therapeutics, Inc.
Mar 31, 2026 BUY Strong Buy
+306.4% avg upside
11 analysts
$20.00
321.11% Upside
-11.3%
AARD
Aardvark Therapeutics, Inc.
Feb 27, 2026 BUY Buy
+298.2% avg upside
12 analysts
$21.00
338.45% Upside
-61.8%
LGND
Ligand Pharma
Feb 27, 2026 BUY Strong Buy
-25.0% avg upside
15 analysts
$277.00
8.81% Downside
+49.2%
VERU
Veru
Feb 12, 2026 BUY Strong Buy
+559.9% avg upside
10 analysts
$25.00
730.56% Upside
+5.8%
CUE
Cue Biopharma
Feb 10, 2026 HOLD Strong Buy
-62.9% avg upside
9 analysts
+127.6%
IMVT
Immunovant
Feb 09, 2026 BUY Strong Buy
-0.5% avg upside
24 analysts
$54.00
38.92% Upside
+38.0%
QNCX
Quince Therapeutics
Nov 14, 2025 BUY Hold
+2250.5% avg upside
15 analysts
$100.00
10498.82% Upside
-93.6%
XERS
Xeris Pharmaceuticals
Nov 07, 2025 BUY Strong Buy
+21.2% avg upside
10 analysts
$18.00
134.04% Upside
-7.1%
RYTM
Rhythm Pharmaceuticals
Nov 04, 2025 HOLD Strong Buy
+10.4% avg upside
19 analysts
-8.7%
BMRN
BioMarin Pharmaceutical
Oct 28, 2025 BUY Strong Buy
+60.3% avg upside
52 analysts
$98.00
66.02% Upside
+4.5%
CGEN
Compugen
Oct 14, 2025 BUY Strong Buy
+153.9% avg upside
8 analysts
$4.00
91.41% Upside
+43.6%
AVTX
Avalo Therapeutics
Sep 29, 2025 BUY Strong Buy
+197.5% avg upside
19 analysts
$35.00
92.33% Upside
+25.6%
TECX
Tectonic Therapeutic
Sep 03, 2025 BUY Strong Buy
+77.4% avg upside
24 analysts
$80.00
150.09% Upside
+70.8%
ALNY
Alnylam Pharma
Aug 04, 2025 BUY Strong Buy
+17.6% avg upside
51 analysts
$490.00
68.08% Upside
-31.7%
NCNA
Nucana
Sep 16, 2024 BUY Buy
+715.8% avg upside
9 analysts
$25.00
1512.89% Upside
-99.7%
TEVA
Teva Pharmaceutical
May 20, 2024 HOLD Buy
-11.6% avg upside
39 analysts
-0.2%
CYTK
Cytokinetics
May 14, 2024 BUY Strong Buy
+5.2% avg upside
36 analysts
$106.00
28.95% Upside
-49.5%
PDSB
PDS Biotechnology
Mar 28, 2024 BUY Strong Buy
+1612.3% avg upside
11 analysts
-68.2%
XFOR
X4 Pharmaceuticals
Dec 18, 2023 BUY Strong Buy
+520.0% avg upside
15 analysts
-8.0%
MIST
Milestone Pharmaceuticals
Nov 13, 2023 BUY Strong Buy
+567.1% avg upside
7 analysts
$11.00
787.16% Upside
-21.4%
GRCE
Grace Therapeutics
Jul 10, 2023 BUY Strong Buy
+153.0% avg upside
9 analysts
+8.9%
CLNN
Clene
Oct 04, 2022 HOLD Strong Buy
+447.6% avg upside
11 analysts
-71.8%
CASIF
CASI Pharmaceuticals
May 26, 2022 BUY Strong Buy
+19387.2% avg upside
5 analysts
$60.00
46053.86% Upside
·
BXRXQ
Baudax Bio
Mar 21, 2022 BUY Strong Buy
+18749999900.0% avg upside
3 analysts
$200.00
19999999899.97% Upside
·
CRBP
Corbus Pharmaceuticals
Nov 16, 2021 HOLD Strong Buy
+309.9% avg upside
20 analysts
-87.9%
WINT
Windtree Therapeutics
Jun 04, 2021 BUY Strong Buy
+48952.7% avg upside
6 analysts
$8.00
57042.77% Upside
·
ATXI
Avenue Therapeutics
Jun 02, 2021 BUY Strong Buy
+6328.6% avg upside
4 analysts
$12.00
4185.78% Upside
·
VCNX
Vaccinex
May 18, 2021 BUY Buy
+808.9% avg upside
2 analysts
$7.00
808.89% Upside
·
CMMB
Chemomab Therapeutics
May 07, 2021 BUY Strong Buy
+1611.8% avg upside
6 analysts
$42.00
2541.45% Upside
-84.7%
TRVN
Trevena
May 06, 2021 HOLD Buy
+949900.0% avg upside
11 analysts
·
AMRN
Amarin
Dec 31, 2020 HOLD Hold
-47.1% avg upside
18 analysts
-31.1%
ADMA
ADMA Biologics
Dec 31, 2020 HOLD Strong Buy
+49.4% avg upside
15 analysts
-27.7%
OTLK
Outlook Therapeutics
Dec 31, 2020 HOLD Buy
+470.6% avg upside
11 analysts
+4.6%
EVFM
Evofem Biosciences
Sep 11, 2020 HOLD Buy
+278863.4% avg upside
8 analysts
·
LITS
Lite Strategy
May 10, 2019 BUY Buy
+1139.3% avg upside
13 analysts
$7.00
679.43% Upside
·
TLPH
Talphera
May 09, 2019 HOLD Buy
+354.6% avg upside
15 analysts
-51.3%
GRDX
GridAI Technologies
Apr 03, 2019 BUY Strong Buy
+359.6% avg upside
7 analysts
$8.00
81.50% Upside
-78.7%
🔒 50 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Leland Gershell — Frequently Asked Questions
How accurate are Leland Gershell's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Leland's ratings were profitable over a one-year hold, with an average return of -9.0% per rating, or -10.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Leland ranked on 13Foresight?
Leland Gershell is currently ranked #2289 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Leland cover?
Leland most recently has ratings on OKUR, ARGX, ENGN, FULC, CAPR, ASND, SABS, SPRB, TARA, URGN, CALC, CLYM and 43 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.